Welcome to LookChem.com Sign In|Join Free

CAS

  • or
L-N-CBZ-3-PYRAZOL-1-YL-ALANINE is a chemical compound derived from alanine, an essential amino acid for protein synthesis in the human body. L-N-CBZ-3-PYRAZOL-1-YL-ALANINE features a pyrazole ring, which endows it with unique structural and functional attributes. It plays a significant role in the pharmaceutical and medicinal fields, primarily as a building block in the synthesis of pharmaceutical drugs and research compounds. Additionally, it contributes to the study of protein structure and function, as well as to drug development and discovery processes. The distinctive characteristics of L-N-CBZ-3-PYRAZOL-1-YL-ALANINE make it a valuable molecule in the realms of biochemistry and medicinal chemistry.

20945-53-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 20945-53-3 Structure
  • Basic information

    1. Product Name: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE
    2. Synonyms: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE;(S)-2-[(Benzyloxycarbonyl)amino]-3-(1H-pyrazol-1-yl)propanoic acid;N-Cbz-3-(Pyrazol-1-yl)-L-alanine;Z-3-(Pyrazol-1-yl)-L-Ala-OH
    3. CAS NO:20945-53-3
    4. Molecular Formula: C14H15N3O4
    5. Molecular Weight: 289.29
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 20945-53-3.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 533.1±50.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.31
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. PKA: 3.49±0.10(Predicted)
    10. CAS DataBase Reference: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE(CAS DataBase Reference)
    11. NIST Chemistry Reference: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE(20945-53-3)
    12. EPA Substance Registry System: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE(20945-53-3)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 20945-53-3(Hazardous Substances Data)

20945-53-3 Usage

Uses

Used in Pharmaceutical Industry:
L-N-CBZ-3-PYRAZOL-1-YL-ALANINE is used as a building block for the synthesis of various pharmaceutical drugs and research compounds. Its unique pyrazole ring structure allows for the creation of novel drug molecules with potential therapeutic applications.
Used in Biochemistry Research:
L-N-CBZ-3-PYRAZOL-1-YL-ALANINE is utilized in the study of protein structure and function. Its incorporation into protein molecules can provide insights into the role of amino acids in protein folding, stability, and function.
Used in Drug Development and Discovery:
L-N-CBZ-3-PYRAZOL-1-YL-ALANINE is employed in drug development and discovery processes. Its unique properties can be leveraged to design and develop new drugs with improved efficacy, selectivity, and safety profiles.

Check Digit Verification of cas no

The CAS Registry Mumber 20945-53-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,0,9,4 and 5 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 20945-53:
(7*2)+(6*0)+(5*9)+(4*4)+(3*5)+(2*5)+(1*3)=103
103 % 10 = 3
So 20945-53-3 is a valid CAS Registry Number.

20945-53-3Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

-

Paragraph 0492-0493, (2017/07/05)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 98, (2012/02/15)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 187, (2011/06/16)

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 99, (2011/06/16)

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 94, (2011/07/07)

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

-

, (2010/04/25)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

-

, (2010/09/05)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

-

, (2010/11/03)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 159; 160, (2010/11/04)

This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 147-148, (2010/12/26)

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 20945-53-3